Similar articles for PMID: 22664653

Year	Number of Results
1998	1
1999	2
2000	2
2001	4
2002	1
2004	3
2005	1
2006	5
2007	12
2008	15
2009	16
2010	24
2011	19
2012	35
2013	46
2014	28
2015	26
2016	31
2017	34
2018	21
2019	22
2020	34
2021	32
2022	16
2023	7
2024	0

1

Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.

Lee SJ, Park HJ, Kim YH, Kim BY, Jin HS, Kim HJ, Han JH, Yim H, Jeong SY. Lee SJ, et al. Int J Mol Med. 2012 Aug;30(2):443-50. doi: 10.3892/ijmm.2012.1013. Epub 2012 May 29. Int J Mol Med. 2012. PMID: 22664653

2

NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Park HJ, Lee SJ, Sohn YB, Jin HS, Han JH, Kim YB, Yim H, Jeong SY. Park HJ, et al. Int J Oncol. 2013 Feb;42(2):657-66. doi: 10.3892/ijo.2012.1751. Epub 2012 Dec 24. Int J Oncol. 2013. PMID: 23292448

3

Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.

Lieber J, Kirchner B, Eicher C, Warmann SW, Seitz G, Fuchs J, Armeanu-Ebinger S. Lieber J, et al. Pediatr Blood Cancer. 2010 Dec 1;55(6):1089-95. doi: 10.1002/pbc.22740. Pediatr Blood Cancer. 2010. PMID: 20680965

4

The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.

Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N. Hikita H, et al. Hepatology. 2010 Oct;52(4):1310-21. doi: 10.1002/hep.23836. Hepatology. 2010. PMID: 20799354

5

The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.

Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A. Witham J, et al. Clin Cancer Res. 2007 Dec 1;13(23):7191-8. doi: 10.1158/1078-0432.CCR-07-0362. Clin Cancer Res. 2007. PMID: 18056200

6

The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells.

Allaman-Pillet N, Oberson A, Munier F, Schorderet DF. Allaman-Pillet N, et al. Ophthalmic Genet. 2013 Mar-Jun;34(1-2):1-13. doi: 10.3109/13816810.2011.615077. Epub 2011 Sep 28. Ophthalmic Genet. 2013. PMID: 21955141

7

The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.

Ezzoukhry Z, Louandre C, François C, Saidak Z, Godin C, Mazière JC, Galmiche A. Ezzoukhry Z, et al. Mol Pharmacol. 2011 Jun;79(6):997-1004. doi: 10.1124/mol.110.070565. Epub 2011 Mar 10. Mol Pharmacol. 2011. PMID: 21393385

8

Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.

Lucas KM, Mohana-Kumaran N, Lau D, Zhang XD, Hersey P, Huang DC, Weninger W, Haass NK, Allen JD. Lucas KM, et al. Clin Cancer Res. 2012 Feb 1;18(3):783-95. doi: 10.1158/1078-0432.CCR-11-1166. Epub 2011 Dec 15. Clin Cancer Res. 2012. PMID: 22173547

9

p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737.

Tagscherer KE, Fassl A, Sinkovic T, Combs SE, Roth W. Tagscherer KE, et al. Apoptosis. 2012 Feb;17(2):187-99. doi: 10.1007/s10495-011-0664-3. Apoptosis. 2012. PMID: 22002102

10

Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.

Hari Y, Harashima N, Tajima Y, Harada M. Hari Y, et al. Oncotarget. 2015 Dec 8;6(39):41902-15. doi: 10.18632/oncotarget.5881. Oncotarget. 2015. PMID: 26506422 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

385 results

Results by year